FTC's Comments On PBMs Are Unproductive, State Legislators Say
This article was originally published in The Pink Sheet Daily
Executive Summary
National Legislative Association on Prescription Drug Prices criticizes the Federal Trade Commission's recent comments on state bills that would mandate greater PBM transparency, claiming FTC ignores evidence of deceptive practices and the need for state regulation.